Longeveron Inc (LGVN) Directors and Executive Officers - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Longeveron Inc   (NASDAQ: LGVN)

Longeveron Inc

Officers & Directors


Neil E. Hare
Director

Lisa A. Locklear
Executive Vice President and Chief Financial Officer

Mohamed Wa el Ahmed Hashad
Chief Executive Officer

Joshua M. Hare
Director

Cathy Ross
Director

Douglas Losordo
Director

Ursula Ungaro
Director

Jeffrey Pfeffer
Director

Khoso Baluch
Director

Rock Soffer
Director

Marcum LLP
Auditor ,

Longeveron Inc currently has 38 employees.

  News about Longeveron Inc Key Personnel

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

Longeveron Inc.: Strategic Movements and Financial Insights Amidst ChallengesLongeveron Inc. a groundbreaking company in the field of cellular therapies, recently released a letter to its shareholders detailing its corporate strategy, significant advancements, and primary objectives for 2025. This communication comes at a crucial time for the organization, which is navigating various challenges in the healthcare landscape, especially as it gears up for a potential Biologics License Application (BLA) that could facilitate the commercialization of its innovative therapies targeting debilitating illnesses such as Alzheimer s disease. Recent Progress and Corporate StrategyThe letter emphasizes Longeveron’s st...

Longeveron Appoints Devin Blass as CTO, Prepares for BLA Filing Amid Financial Challenges and Focus on Alzheimer’s Therapy,

In a significant move aimed at bolstering its strategic framework and advancing its scientific endeavors, Longeveron Inc. a pioneering entity in cellular therapies, has announced the appointment of Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing and Controls (CMC), effective December 2, 2024. This transition comes at a pivotal moment for the company as it prepares for a potential Biologics License Application (BLA) filing, which could pave the way for the commercialization of its innovative therapies designed to combat debilitating diseases such as Alzheimer’s.The appointment of Blass, a seasoned expert in the field, underscores Longeveron’s commitment ...

Longeveron Inc's Corporate Strategy and Funding Efforts Pave the Way for Cellular Therapies Advancements


Miami-based biotechnology company, Longeveron Inc. (NASDAQ: LGVN), recently issued a letter to shareholders highlighting its corporate strategy, clinical pipeline, and 2024 key priorities and goals. The company s CEO expressed optimism about the future, despite recording a significant cumulative net loss of $-20 million during the 12 months ending in the third quarter of 2023, resulting in a negative return on equity (ROE) of -147.9%.
Within the Major Pharmaceutical Preparations industry, Longeveron Inc. ranked relatively low in terms of return on equity compared to its peers, with 321 other companies surpassing its performance. Moreover, the company s total ranking in ROE deteriorated in the third ...






LGVN Management Effectiveness LGVN Revenue per Employee LGVN Income per Employee


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.